- Trial phase
- Approved / marketed (originally approved Feb 2013); still used as the comparator/backbone arm in other sponsors' Phase 3
- Time to market
- Already marketed, FDA approval catalyst recorded 2013-02-08; generic pomalidomide (Camber Pharmaceuticals, ANDA210236) already has U.S. labeling, so the brand's exclusivity is gone.
- Why 2/10
- No hard, dated catalyst exists for Pomalyst itself in the next ~12 months (it was approved on 2013-02-08 and faces generic competition), and it is a small, declining slice of a mega-cap's portfolio, so it cannot drive BMY's share price; score 2 (approved, minor program within a large pipeline, nothing scheduled).
Do not trade BMY on Pomalyst, there is no pending approval, readout, or label decision for this drug. Watch BMS quarterly filings (latest 10-Q filed 2026-07-30) for Pomalyst/Imnovid sales erosion vs. generics, and note that the real near-term myeloma catalyst for the ticker is a DIFFERENT molecule: BMY's next-gen IMiD iberdomide has a PDUFA of 2026-08-17 per SecBot event data. An AbbVie Phase 3 (venetoclax vs. pomalidomide+dex, NCT03539744) has an estimated primary completion of August 2026 and uses Pomalyst as the comparator arm.
Price Chart
Executive Summary
Pomalyst (pomalidomide; Imnovid in the EU) is BMS's oral immunomodulatory drug for relapsed/refractory multiple myeloma, originally developed by Celgene and acquired by Bristol Myers Squibb, the FDA-approval catalyst is recorded 2013-02-08 in SecBot's catalyst data. It is a mature product now facing generic competition (FDA safety-labeling data, effective 2026-03-04, for generic pomalidomide from Camper/Camber Pharmaceuticals under ANDA210236) and is one small product inside a ~$65/share mega-cap trading at a hold consensus with a mean target ($64.91) roughly flat to price, so the drug itself has no scheduled binary catalyst and little ability to move BMY.
How It Works
Pomalyst is a pill in the thalidomide family of "IMiD" immunomodulatory drugs. It helps the immune system attack cancer, cuts off blood-vessel growth that feeds tumors, and directly stresses myeloma cells. It is given with the steroid dexamethasone to treat multiple myeloma that has relapsed or stopped responding after earlier therapies.
Trial Status
SecBot trial data shows no new BMS pivotal trial of pomalidomide itself: BMS/Celgene Phase 3 NCT03651128 (bb2121 vs. pomalidomide-containing standard regimens, 386 enrolled) completed 2026-04-13; Celgene Phase 2 NCT01946477 (pomalidomide+dex ± daratumumab, 186 enrolled) completed; AbbVie Phase 3 NCT03539744 (venetoclax+dex vs. pomalidomide+dex, 265 enrolled) active, est. primary completion 2026-08; a Phase 2 Kaposi sarcoma study (NCT03601806) completed 2025-04.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for Pomalyst itself (no PDUFA/pivotal readout for this molecule in the next ~12 months).
- BMY-level context (different molecule): iberdomide PDUFA 2026-08-17 for relapsed/refractory multiple myeloma.
- Competitor readout using Pomalyst as comparator: AbbVie venetoclax+dex vs. pomalidomide+dex Phase 3 (NCT03539744), estimated primary completion 2026-08.
- BMS quarterly results (10-Q filed 2026-07-30; next quarterly 10-Q) for Pomalyst/Imnovid sales trends.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report